Francesco Marrafino

Francesco Marrafino

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2019 in Polymers
Verified
Journal Article
Open access
PDF file
Rosita DianaRosita Diana
Rosita Diana
Barbara PanunziBarbara Panunzi
Barbara Panunzi
Simona ConcilioSimona Concilio
Simona Concilio
FMFrancesco Marrafino
Francesco Marrafino
Rafi ShiklerRafi Shikler
Rafi Shikler
Ugo CarusoUgo Caruso
Ugo Caruso
From a dicyano-phenylenevinylene (PV) and an azobenzene (AB) skeleton, two new symmetrical salen dyes were obtained. Terminal bulky substituents able to reduce intermolecular interactions and flexible tails to guarantee solubility were added to the fluorogenic cores. Photochemical performances were investigated on the small molecules in solution, as neat crystals and as dopants in polymeric matrixes. High fluorescence quantum yield in the orange-red region was observed for the brightest emissive films (88% yield). The spectra of absorption and fluorescence were predicted by Density Functional Theory (DFT) calculations. The predicted energy levels of the frontier orbitals are in good agreement with voltammetry and molecular spectroscopy measures. Employing the two dyes as dopants of a nematic polymer led to remarkable orange or yellow luminescence, which dramatically decreases in on-off switch mode after liquid crystal (LC) order was lost. The fluorogenic cores were also embedded in organic polymers and self-assembly zinc coordination networks to transfer the emission properties to a macro-system. The final polymers emit from red to yellow both in solution and in the solid state and their photoluminescence (PL) performance are, in some cases, enhanced when compared to the fluorogenic cores.

23 August 2022 in Bioinformatics
Verified
Journal Article
Closed access
PDF file
ASArkadeep Sarkar
Arkadeep Sarkar
JSJacopo Santoro
Jacopo Santoro
LBLuigi Di Biasi
Luigi Di Biasi
FMFrancesco Marrafino
Francesco Marrafino
Stefano PiottoStefano Piotto
Stefano Piotto
A graphical user interface for the GROMACS program has been developed as plugins for YASARA molecular graphics suite. The most significant GROMACS methods can be run entirely via a windowed menu system, and the results are shown on screen in real time. YAMACS is written in Python and is freely available for download at https://github.com/YAMACS-SML/YAMACS and is supported on Linux. It has been released under GPL-3.0 license. Supplementary data are available at Bioinformatics online.

22 June 2023 in Journal of Computational Chemistry
Verified
Journal Article
Open access
ASArkadeep Sarkar
Arkadeep Sarkar
Lucia SessaLucia Sessa
Lucia Sessa
FMFrancesco Marrafino
Francesco Marrafino
Stefano PiottoStefano Piotto
Stefano Piotto
The accuracy of quantum mechanics (QM) simulations depends heavily on the quality of initial input files. Despite the popularity of QM simulation packages, achieving precise results still heavily relies on the user's proficiency in preparing the QM simulation systems. In this work, we present an easy‐to‐use tool called GUIDE, a YASARA plugin to assist researchers in quantum chemistry workflow automation using ORCA and MOPAC simulation packages. GUIDE lets users compute complex QM calculation workflows via an automated graphical window system. It allows for a more integrated and streamlined research process, as researchers can easily access all the necessary tools within one software without switching between multiple programs. This tool can save time and increase efficiency in computational chemistry methods. GUIDE is written in Python and is freely available for download at https://github.com/YAMACS-SML/GUIDE. The plugin is released under a GPL‐3.0 license and is supported on Windows and Linux.

28 July 2023 in Computational Biology and Chemistry
Verified
Journal Article
Open access
Lucia SessaLucia Sessa
Lucia Sessa
Simona ConcilioSimona Concilio
Simona Concilio
FMFrancesco Marrafino
Francesco Marrafino
ASArkadeep Sarkar
Arkadeep Sarkar
RDRosita Diana
Rosita Diana
SPStefano Piotto
Stefano Piotto
Valinomycin is a potent ionophore known for its ability to transport potassium ions across biological membranes. The study focuses on the hydroxylated analogues of valinomycin (HyVLMs) and compares their energy profiles and capabilities for transporting potassium ions across phospholipid membranes. Using metadynamics, we investigated the energy profiles of wildtype valinomycin (VLM_1) and its three hydroxylated analogues (VLM_2, VLM_3, and VLM_4). We observed that all analogues exhibited energy maxima in the centre of the membrane and preferred positions below the phospholipid heads. Furthermore, the entry barriers for membrane penetration were similar among the analogues, suggesting that the hydroxyl group did not significantly affect their passage through the membrane. Transition state calculations provided insights into the ability of valinomycin analogues to capture potassium ions, with VLM_4 showing the lowest activation energy and VLM_2 displaying the highest. Our findings contribute to understanding the mechanisms of potassium transport by valinomycin analogues and highlight their potential as ionophores. The presence of the hydroxyl group is of particular importance because it paves the way for subsequent chemical modifications and the synthesis of new antiviral agents with reduced intrinsic toxicity.

2 August 2021 in Journal of Medical Internet Research
Verified
Journal Article
Open access
Stefano PiottoStefano Piotto
Stefano Piotto
LBLuigi Di Biasi
Luigi Di Biasi
FMFrancesco Marrafino
Francesco Marrafino
Simona ConcilioSimona Concilio
Simona Concilio
Background: During the 2020s, there has been extensive debate about the possibility of using contact tracing (CT) to contain the SARS-CoV-2 pandemic, and concerns have been raised about data security and privacy. Little has been said about the effectiveness of CT. In this paper, we present a real data analysis of a CT experiment that was conducted in Italy for 8 months and involved more than 100,000 CT app users. Objective: We aimed to discuss the technical and health aspects of using a centralized approach. We also aimed to show the correlation between the acquired contact data and the number of SARS-CoV-2–positive cases. Finally, we aimed to analyze CT data to define population behaviors and show the potential applications of real CT data. Methods: We collected, analyzed, and evaluated CT data on the duration, persistence, and frequency of contacts over several months of observation. A statistical test was conducted to determine whether there was a correlation between indices of behavior that were calculated from the data and the number of new SARS-CoV-2 infections in the population (new SARS-CoV-2–positive cases). Results: We found evidence of a correlation between a weighted measure of contacts and the number of new SARS-CoV-2–positive cases (Pearson coefficient=0.86), thereby paving the road to better and more accurate data analyses and spread predictions. Conclusions: Our data have been used to determine the most relevant epidemiological parameters and can be used to develop an agent-based system for simulating the effects of restrictions and vaccinations. Further, we demonstrated our system's ability to identify the physical locations where the probability of infection is the highest. All the data we collected are available to the scientific community for further analysis.

28 July 2021 in Journal of General Virology
Verified
Journal Article
Open access
MPMarie O. Pohl
Marie O. Pohl
IBIdoia Busnadiego
Idoia Busnadiego
FMFrancesco Marrafino
Francesco Marrafino
LWLars Wiedmer
Lars Wiedmer
AHAnnika Hunziker
Annika Hunziker
SSSilke Stertz
Silke Stertz
Rapid repurposing of existing drugs as new therapeutics for COVID-19 has been an important strategy in the management of disease severity during the ongoing SARS-CoV-2 pandemic. Here, we used high-throughput docking to screen 6000 compounds within the DrugBank library for their potential to bind and inhibit the SARS-CoV-2 3 CL main protease, a chymotrypsin-like enzyme that is essential for viral replication. For 19 candidate hits, parallel in vitro fluorescence-based protease-inhibition assays and Vero-CCL81 cell-based SARS-CoV-2 replication-inhibition assays were performed. One hit, diclazuril (an investigational anti-protozoal compound), was validated as a SARS-CoV-2 3 CL main protease inhibitor in vitro (IC50 value of 29 µM) and modestly inhibited SARS-CoV-2 replication in Vero-CCL81 cells. Another hit, lenvatinib (approved for use in humans as an anti-cancer treatment), could not be validated as a SARS-CoV-2 3 CL main protease inhibitor in vitro, but serendipitously exhibited a striking functional synergy with the approved nucleoside analogue remdesivir to inhibit SARS-CoV-2 replication, albeit this was specific to Vero-CCL81 cells. Lenvatinib is a broadly-acting host receptor tyrosine kinase (RTK) inhibitor, but the synergistic effect with remdesivir was not observed with other approved RTK inhibitors (such as pazopanib or sunitinib), suggesting that the mechanism-of-action is independent of host RTKs. Furthermore, time-of-addition studies revealed that lenvatinib/remdesivir synergy probably targets SARS-CoV-2 replication subsequent to host-cell entry. Our work shows that combining computational and cellular screening is a means to identify existing drugs with repurposing potential as antiviral compounds. Future studies could be aimed at understanding and optimizing the lenvatinib/remdesivir synergistic mechanism as a therapeutic option.